iCAD Expands CAD Technology Agreement with 3D Imaging Partner TeraRecon


Partnership Reflects Combined CT Colon Technological Advances --

NASHUA, N.H. and SAN MATEO, Calif., Sept. 13 /PRNewswire-FirstCall/ -- iCAD(R), Inc. (NASDAQ:ICAD), an industry-leading provider of Computer-Aided Detection (CAD) solutions that enable healthcare professionals to identify cancer and other life-threatening conditions earlier, today announced the broadening of its technology partnership with TeraRecon, Inc., a leader in advanced image processing and 3D visualization techniques.

Under the terms of the agreement, iCAD will integrate with TeraRecon's Aquarius 3D tools its Computed Tomography (CT) Colon CAD software for the identification of potential polyps in CT Colonography (CTC) images. TeraRecon is developing a new image processing server to work in concert with existing PACS and DICOM review equipment, which will include iCAD's detection software tools for both lung and colon applications. Processing results will be delivered to TeraRecon's Aquarius Workstation to enhance the review, analysis and visualization capabilities available to the radiologist.

"By combining TeraRecon's powerful 3D visualization tools with iCAD's advanced colon polyp detection software, we intend to set a new standard of patient care by providing physicians with a more comprehensive toolkit designed to reduce reading time and improve clinical confidence," said TeraRecon COO, Robert Taylor.

The American Cancer Society states that colorectal cancer is the third most commonly diagnosed cancer and the second most common cause of cancer death in the United States. In 2005, it is expected that 145,290 new cases will be identified and colorectal cancer will result in approximately 56,000 deaths. While the five-year survival rate for all stages of colorectal cancer is 64%, the rate increases to 90% when identified early. It is believed that a mere 39% of colorectal cancer is found at this early stage today.

"With the American Cancer Society estimating that only 30% of the at-risk population currently participating in colorectal screening, CT Colonography offers patients a non-invasive alternative that has proven to be effective in detecting colorectal cancer," said W. Scott Parr, President and CEO of iCAD, Inc. "By partnering with leading companies like TeraRecon, we believe our innovative CAD technology can advance the utilization of CTC exams and ultimately impact the colorectal cancer survival rate."

iCAD's CT Colon CAD software is currently under development and is expected to be ready for distribution in 2006, pending regulatory review and approval by the US Food and Drug Administration (FDA). iCAD and TeraRecon previously announced plans for the integration and distribution of lung CAD software through the new processing server addition to the Aquarius product line. TeraRecon's Aquarius workstation provides advanced 3D and image processing capability for radiologists, while the AquariusNET server provides a central 3D processing resource accessed through thin-client software installed on regular PCs throughout the healthcare enterprise. TeraRecon's Aquarius 3D products have earned widespread clinical acceptance with over 1000 licenses sold worldwide.

All intended use statements are pending approval from the FDA.

About TeraRecon, Inc.

TeraRecon Inc., a leader in advanced image processing and 3D visualization techniques, provides advanced imaging systems for medical and other visualization applications based on its unique and patented image processing technologies. A two-time winner of Frost and Sullivan Innovation Awards, the company has developed a leading portfolio of products that advance the performance, quality, functionality, and integration of medical imaging and 3D visualization systems. Founded in 1997, TeraRecon has developed a unique family of powerful processors that are used in its real time family of 3D diagnostic workstations, enterprise-wide 3D imaging servers; color Doppler Ultrasound systems, high-performance image reconstruction solutions, and real- time 3D volume rendering hardware engines. TeraRecon is a fast growing, privately held company with headquarters in San Mateo, CA, and branch offices in Concord, MA, Tokyo, Japan, and Osaka, Japan.

For more information about TeraRecon, call 650-372-1100 or visit www.terarecon.com/.

About iCAD, Inc.

iCAD, Inc. is an industry-leading provider of Computer-Aided Detection (CAD) solutions that enable healthcare professionals to identify cancer and other life-threatening conditions earlier by making medical services more effective, more accessible and more affordable for patients worldwide. Recipient of Frost & Sullivan's Growth Strategy Leadership award, iCAD offers a comprehensive range of high-performance, upgradeable CAD systems for the high, mid and low volume mammography markets. As the most frequently selected CAD solution for film-based and digital breast screening, iCAD is entrusted with the task of early cancer detection by over a thousand women's healthcare centers worldwide. For more information, call +1 877 iCADnow or visit http://www.icadmed.com/.

For iCAD investor relations, contact Kevin McGrath of Cameron Associates at +1 212 245 4577 or via email at kevin@cameronassoc.com.

For all other iCAD inquires, contact Monica Pandolfi of SHIFT Communications at +1 617 681 1235 or via email at mpandolfi@shiftcomm.com.

All Topics